Market Size of Global Genitourinary Drugs Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 2.90 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Low |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Genitourinary Drugs Market Analysis
The genitourinary drugs market is expected to grow at a CAGR of 2.9% during the forecast period.
Initially, COVID-19 impacted the studied market owing to cancellations of elective procedures, including genitourinary tract infection treatments. Also, COVID-19 infection had been reported to worsen the symptoms of people with genitourinary disorders. For instance, according to an article published in the Asian Journal of Urology in July 2021, coronaviruses could cause urological symptoms when they infect the genitourinary system. COVID-19 was responsible for genitourinary organ dysfunction and damage. Patients with COVID-19 were found to have kidney impairment in several studies. Some research studies indicated that COVID-19 infection poses the greatest threat to the respiratory, digestive, and reproductive systems. Therefore, the genitourinary market was significantly impacted by COVID-19 in its initial phase. However, post-pandemic, the market started to recover since the restrictions were lifted and elective procedures resumed worldwide. The market is expected to gain pace during the forecast period owing to rising research and development activities for innovation in genitourinary drugs.
The high burden of genitourinary disorders is expected to create opportunities for market players' product innovation and launches which is expected to propel market growth. For instance, as per the report published by the World Health Organization in November 2021, more than 1.0 million sexually transmitted infections are acquired globally and most of them are asymptomatic. Sexually transmitted infections (STIs) are associated with genitourinary complications which are projected to propel the demand for developing a genitourinary drug for the effective treatment of such diseases, thereby fueling the growth of the market.
Furthermore, the high prevalence of urinary tract infections and urinary incontinence is also contributing to the market growth. For instance, according to a Statpearls article updated in August 2022, it is estimated that around 423 million people (20 years and older) worldwide experience some form of urinary incontinence. The high burden of urinary incontinence globally is expected to propel the market growth.
Additionally, increasing investments in research and developments (R&D) activities for developing novel molecules for treating genitourinary diseases, and an increasing number of pipeline drugs are expected to drive the market during the forecast period. For instance, in February 2022, Asieris Pharmaceuticals received the clinical trial application (CTA) approval for Hexvix, a drug for the diagnosis of bladder cancer, from the National Medical Products Administration (NMPA) of China.
However, increasing counterfeit drugs and a lack of awareness about infections and treatment medications are expected to restrain the genitourinary drug market.
Genitourinary Drugs Industry Segmentation
As per the scope of the report, genitourinary drugs are used to treat disorders affecting the kidneys, bladder, ureters, and urethra. Patients suffering from diseases and infections related to genitourinary systems have been depending on steroids and immunosuppressants, which are chemically synthesized and may reciprocate with severe side effects such as insomnia, acne, nausea, vomiting, and diarrhea.
The Genitourinary Drugs Market is Segmented by Disease Type (Erectile dysfunction, Gonorrhoea, Genital Herpes, Urinary Tract Infections, Urinary Incontinence, Glomerulonephritis, Chronic renal failure, Other Disease Types), Drug Type (Hormonal Therapy, Impotence Agents, Uterine Relaxants, Urinary Antispasmodics, Urinary pH Modifiers, Uterine Stimulants, Miscellaneous Genitourinary Tract Agents), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major global regions. The report offers the value (USD million) for the above segments.
| By Disease Type | |
| Erectile dysfunction | |
| Gonorrhoea | |
| Genital Herpes | |
| Urinary Tract Infections | |
| Urinary Incontinence | |
| Glomerulonephritis | |
| Chronic renal failure | |
| Other Disease Types |
| By Drug Type | |
| Hormonal Therapy | |
| Impotence Agents | |
| Uterine Relaxants | |
| Urinary Antispasmodics | |
| Urinary pH Modifiers | |
| Uterine Stimulants | |
| Miscellaneous Genitourinary Tract Agents |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Global Genitourinary Drugs Market Size Summary
The genitourinary drugs market is poised for growth, driven by increasing research and development activities aimed at innovating treatments for genitourinary disorders. The market experienced initial setbacks due to the COVID-19 pandemic, which led to the cancellation of elective procedures and exacerbated symptoms in patients with genitourinary conditions. However, as restrictions lifted and procedures resumed, the market began to recover. The high prevalence of sexually transmitted infections and urinary tract issues is expected to create significant opportunities for product innovation and launches, propelling market expansion. The demand for effective treatments is further fueled by the global burden of urinary incontinence and the need for novel therapeutic solutions.
North America is anticipated to hold a substantial share of the market, supported by a high prevalence of genitourinary diseases, robust healthcare infrastructure, and increased awareness. The region's market growth is bolstered by strategic initiatives from key players, including significant investments in research and development, new product launches, and collaborations. The approval of new drugs and the development of novel antibiotics for urinary tract infections are expected to enhance market dynamics. Despite challenges such as counterfeit drugs and limited awareness, the competitive landscape remains active, with major companies like Merck & Co. Inc., Pfizer, and Cipla Inc. leading efforts to strengthen their market positions through innovative strategies.
Global Genitourinary Drugs Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Increasing Prevalence of Genitourinary Disorders
-
1.2.2 Increasing Number of Pipeline Products
-
-
1.3 Market Restraints
-
1.3.1 Lack of Therapy Compliance
-
1.3.2 Increasing Advent of Counterfeit Drugs
-
-
1.4 Porter's Five Forces Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION (Market Size by Value - USD million)
-
2.1 By Disease Type
-
2.1.1 Erectile dysfunction
-
2.1.2 Gonorrhoea
-
2.1.3 Genital Herpes
-
2.1.4 Urinary Tract Infections
-
2.1.5 Urinary Incontinence
-
2.1.6 Glomerulonephritis
-
2.1.7 Chronic renal failure
-
2.1.8 Other Disease Types
-
-
2.2 By Drug Type
-
2.2.1 Hormonal Therapy
-
2.2.2 Impotence Agents
-
2.2.3 Uterine Relaxants
-
2.2.4 Urinary Antispasmodics
-
2.2.5 Urinary pH Modifiers
-
2.2.6 Uterine Stimulants
-
2.2.7 Miscellaneous Genitourinary Tract Agents
-
-
2.3 Geography
-
2.3.1 North America
-
2.3.1.1 United States
-
2.3.1.2 Canada
-
2.3.1.3 Mexico
-
-
2.3.2 Europe
-
2.3.2.1 Germany
-
2.3.2.2 United Kingdom
-
2.3.2.3 France
-
2.3.2.4 Italy
-
2.3.2.5 Spain
-
2.3.2.6 Rest of Europe
-
-
2.3.3 Asia-Pacific
-
2.3.3.1 China
-
2.3.3.2 Japan
-
2.3.3.3 India
-
2.3.3.4 Australia
-
2.3.3.5 South Korea
-
2.3.3.6 Rest of Asia-Pacific
-
-
2.3.4 Middle East and Africa
-
2.3.4.1 GCC
-
2.3.4.2 South Africa
-
2.3.4.3 Rest of Middle East and Africa
-
-
2.3.5 South America
-
2.3.5.1 Brazil
-
2.3.5.2 Argentina
-
2.3.5.3 Rest of South America
-
-
-
Global Genitourinary Drugs Market Size FAQs
What is the current Global Genitourinary Drugs Market size?
The Global Genitourinary Drugs Market is projected to register a CAGR of 2.9% during the forecast period (2024-2029)
Who are the key players in Global Genitourinary Drugs Market?
Melinta Therapeutics Inc., Merck & Co. Inc., Pfizer Inc., GlaxoSmithKline and Cipla Inc. are the major companies operating in the Global Genitourinary Drugs Market.
